Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Ludwig-Maximilians - University of Munich
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01239992CT.gov Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hyperlipoproteinemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Laropiprant (this asset) | Ludwig-Maximilians - University of Munich | Approved | B · 63 |
| Niacin | Ludwig-Maximilians - University of Munich | P4 | B |
| Isis-681257 (Galnac3--Conjugated Aso Targeting Human Lipoprotein (A) ) | University Medical Centre Ljubljana | N/A | D |
| Evolocumab | University Medical Centre Ljubljana | N/A | D |
| Alirocumab | University Medical Centre Ljubljana | N/A | D |
Other indications for Laropiprant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Coronary Artery Disorder | — | P3 | B · 62 |
| Cardiovascular Disorder | — | P3 | B · 61 |
| Peripheral Arterial Disease | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Laropiprant in Hyperlipoproteinemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/laropiprant-hyperlipoproteinemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →